GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (FRA:ISI) » Definitions » Shiller PE Ratio

Ionis Pharmaceuticals (FRA:ISI) Shiller PE Ratio : (As of May. 13, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ionis Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Ionis Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Shiller PE Ratio Chart

Ionis Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ionis Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ionis Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Ionis Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ionis Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Shiller PE Ratio falls into.



Ionis Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ionis Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Ionis Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.902/129.4194*129.4194
=-0.902

Current CPI (Mar. 2024) = 129.4194.

Ionis Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.074 100.560 -0.095
201409 -0.178 100.428 -0.229
201412 0.203 99.070 0.265
201503 -0.129 99.621 -0.168
201506 0.258 100.684 0.332
201509 -0.267 100.392 -0.344
201512 -0.542 99.792 -0.703
201603 -0.467 100.470 -0.602
201606 -0.418 101.688 -0.532
201609 0.053 101.861 0.067
201612 0.199 101.863 0.253
201703 0.065 102.862 0.082
201706 -0.018 103.349 -0.023
201709 -0.017 104.136 -0.021
201712 0.017 104.011 0.021
201803 -0.008 105.290 -0.010
201806 -0.248 106.317 -0.302
201809 -0.026 106.507 -0.032
201812 1.943 105.998 2.372
201903 0.549 107.251 0.662
201906 -0.009 108.070 -0.011
201909 0.163 108.329 0.195
201912 1.152 108.420 1.375
202003 -0.253 108.902 -0.301
202006 -0.160 108.767 -0.190
202009 -0.153 109.815 -0.180
202012 -2.006 109.897 -2.362
202103 -0.538 111.754 -0.623
202106 -0.473 114.631 -0.534
202109 -0.493 115.734 -0.551
202112 1.248 117.630 1.373
202203 -0.418 121.301 -0.446
202206 -0.700 125.017 -0.725
202209 -0.333 125.227 -0.344
202212 -0.349 125.222 -0.361
202303 -0.813 127.348 -0.826
202306 -0.554 128.729 -0.557
202309 -0.965 129.860 -0.962
202312 -0.055 129.419 -0.055
202403 -0.902 129.419 -0.902

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ionis Pharmaceuticals  (FRA:ISI) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ionis Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ionis Pharmaceuticals (FRA:ISI) Business Description

Traded in Other Exchanges
Address
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Ionis Pharmaceuticals (FRA:ISI) Headlines

No Headlines